Clinical trial
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract…
NCT00423150 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00423150 |
|---|---|
| Title | Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) |
| Official title | A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasm, Head and Neck Neoplasm, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasm |
| Intervention type | Drug |
| Interventions | Temozolomide |
| Enrollment | 86 |
| Start date | Jan 26, 2007 |
| Primary completion | Jun 11, 2009 |
| Completion | Jun 11, 2009 |
| First posted | Jan 18, 2007 |
| Last update posted | Jun 8, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: